Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2020-11-11 Earnings Release
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
MorphoSys Reports Nine Months and Third Quarter 2020 Results
Earnings Release Classification · 1% confidence The document is titled "MorphoSys Reports Nine Months and Third Quarter 2020 Results" and contains detailed financial figures for the first nine months and the third quarter of 2020, including revenue, EBIT, liquidity, and updated financial guidance for the full year 2020. It also includes operational updates on drug programs. This structure—comprehensive financial reporting for a period shorter than a full year, released mid-year—is characteristic of an Interim/Quarterly Report. The presence of specific financial metrics and the reporting period (Nine Months/Third Quarter) strongly points to the 'Interim / Quarterly Report' category (IR), rather than just an 'Earnings Release' (ER) which typically contains only highlights. 9M 2020
2020-11-11 English
MorphoSys and Cherry Biolabs Announce licensing of Hemibody Technology
M&A Activity Classification · 1% confidence The document is a 'Media Release' dated November 11, 2020, announcing a licensing agreement between MorphoSys AG and Cherry Biolabs regarding Hemibody Technology. It is structured as a news announcement, detailing a business development (licensing deal) rather than a mandatory periodic financial filing (like 10-K or IR) or a specific shareholder event material (like DEF 14A or AGM-R). It does not fit the definitions for ER (Earnings Release), CT (Call Transcript), or AR (Audit Report). Since it is a general corporate announcement about a strategic business development that doesn't fit the more specific categories (like M&A, Financing, or Management changes), the most appropriate classification is the general regulatory announcement/news category, RNS (Regulatory Filings), which serves as a fallback for miscellaneous corporate news distributed via services like DGAP.
2020-11-11 English
Xencor, MorphoSys and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab
Regulatory Filings Classification · 1% confidence The document is titled 'News Details' and begins with a headline announcing a 'Global Development Collaboration' between three pharmaceutical companies (Xencor, MorphoSys, and Incyte) regarding drug development. It is dated November 11, 2020, and is explicitly labeled as a 'Media Release'. It discusses clinical trials, licensing agreements, and future development plans, which are typical components of corporate news releases concerning strategic partnerships or clinical progress. Since it is a press release announcing a strategic business development (a collaboration) rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a specific shareholder communication (like DEF 14A or DVA), it fits best under the general category for corporate announcements or news releases. Given the provided definitions, 'Regulatory Filings (RNS)' is the most appropriate fallback for general corporate news that doesn't fit the highly specific categories like ER, CT, or CAP, although it is a strategic announcement. However, since it details a significant business development (collaboration/licensing), it is a form of corporate news. If 'RNS' is used as a general regulatory/news announcement bucket, it applies. If we look closely at the content, it is a press release announcing a clinical collaboration and licensing terms, which often falls under general corporate news or regulatory disclosure depending on jurisdiction. Given the options, RNS serves as the best general regulatory/news announcement category for non-standard reports. It is not an ER (no financial results), not a CT (no Q&A transcript), and not a CAP (it's a collaboration, not a direct financing event). Therefore, RNS is the most suitable classification for this corporate news release.
2020-11-11 English
Declaration of Voting Results & Voting Rights Announcements 2020
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables reporting changes in share ownership ('Notification of Major Holdings') by a specific entity (Invesco Ltd.) in MorphoSys AG, referencing German Securities Trading Act (WpHG) sections. This directly corresponds to the definition of reporting changes in significant share ownership thresholds. The closest matching category is 'Major Shareholding Notification' (MRQ). Although it mentions 'Voting Rights Announcement' in the header, MRQ specifically covers changes in major holdings, which is the core content here.
2020-11-06 English
Declaration of Voting Results & Voting Rights Announcements 2020
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables regarding the 'Notification of Major Holdings' under German securities law (WpHG). It details changes in the percentage of voting rights held by Invesco Ltd. and its subsidiaries, crossing or reaching a threshold. This directly corresponds to the definition of reporting changes in significant share ownership levels, which maps to the Major Shareholding Notification category (MRQ). Although it is distributed via DGAP (which might suggest RNS), the specific content is a major holding notification.
2020-11-06 English
Declaration of Voting Results & Voting Rights Announcements 2020
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Notification of Major Holdings' and details changes in voting rights percentages (crossing thresholds) held by Invesco Ltd. in MorphoSys AG, referencing German Securities Trading Act (WpHG) articles. This type of filing, which reports changes in significant share ownership, directly corresponds to the definition of a Major Shareholding Notification. The document header also mentions 'Voting Rights Announcements', which aligns with this category, although 'MRQ' is the specific code for major shareholding notifications.
2020-11-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.